Cesca CLI Feasibility Study Published in Peer-Reviewed Journal
20 March 2017 - 9:00PM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced the publication in a peer reviewed journal of data
from its Critical Limb Ischemia (CLI) feasibility study utilizing
the Company’s innovative point-of-care technology. The report was
published in the “Stem Cells International” and is available online
at https://www.hindawi.com/journals/sci/2017/4137626/ref/.
Results from the seventeen patient clinical
study titled, “Safety and Effectiveness of Bone Marrow Cell
Concentrate in the Treatment of Chronic Critical Limb Ischemia
Utilizing a Rapid Point-of-Care System”, (the “Study”) were
obtained using Cesca’s automated point-of-care technology. The
single treatment procedure was performed at the patient’s bedside
and took less than 60 minutes. The Study results showed significant
improvement in wound healing, rest pain and six-minute walking
distance, along with significant reduction in intermittent
claudication pain following the treatment.
Dr. Venkatesh Ponemone, Study Director and
Executive Director of TotipotentRX, a Cesca subsidiary and the
corresponding author of the article commented, “We are targeting
difficult to treat or life threatening conditions such as CLI with
our autologous, cell-based therapies. We believe our innovative
point-of-care cell processing systems, such as those used in the
Study, can play an important role in optimizing the quality and
quantity of target cells used to improve patient outcomes.”
Dr. Xiaochun "Chris" Xu, Cesca's Interim CEO
added, “We are pleased that the Study was recognized and published
in a peer reviewed journal. The encouraging data highlights Cesca’s
capability to develop effective automated cellular processing
systems. We welcome strategic partners to help us further refine
their use in larger clinical settings.”
About Cesca Therapeutics
Inc.Cesca Therapeutics Inc. (www.cescatherapeutics.com) is
engaged in the research, development, and commercialization of
cellular therapies and delivery systems for use in regenerative
medicine. The Company is a leader in the development and
manufacture of automated blood and bone marrow processing systems
that enable the separation, processing and preservation of cell and
tissue therapeutics. These include:
- The SurgWerks™ System (in development) - a
proprietary system comprised of the SurgWerks Processing Platform,
including devices and analytics, and indication-specific SurgWerks
Procedure Kits for use in regenerative stem cell therapy at the
point-of-care for vascular and orthopedic diseases.
- The CellWerks™ System (in development) - a
proprietary cell processing system with associated analytics for
intra-laboratory preparation of adult stem cells from bone marrow
or blood.
- The AXP® System - a proprietary automated
device and companion sterile disposable for concentrating
hematopoietic stem cells from cord blood.
- The MXP® System - a
proprietary automated device and companion sterile disposable for
the isolation and concentration of hematopoietic stem cells from
bone marrow.
- The BioArchive® System - an automated
cryogenic device used by cord blood banks for the cryopreservation
and storage of cord blood stem cell concentrate for future
use.
- Manual bag sets for use in the processing and
cryogenic storage of cord blood.
Forward-Looking StatementThe
statements contained herein may include statements of future
expectations and other forward-looking statements that are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. A more complete description of risks
that could cause actual events to differ from the outcomes
predicted by Cesca Therapeutics' forward-looking statements is set
forth under the caption "Risk Factors" in Cesca Therapeutics annual
report on Form 10-K and other reports it files with the Securities
and Exchange Commission from time to time, and you should consider
each of those factors when evaluating the forward-looking
statements.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
lroth@theruthgroup.com / tbui@theruthgroup.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2024 to May 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From May 2023 to May 2024